Visual Abstract: Fulvestrant-Palbociclib vs. Letrozole-Palbociclib as Initial Therapy for Advanced Breast Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 7, 2021

Media advisory: The full study is linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.4301?guestAccessKey=4c8d31e5-75de-4219-ac23-dc4434ce706d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100721

 

Visual Abstract

 

Authors: Antonio Llombart-Cussac, M.D., of the Hospital Arnau de Vilanova, in Valencia, Spain, is the corresponding author.

(doi:10.1001/jamaoncol.2021.4301)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.